Skip to main content

Table 2 Prospective associations of plasma tran-fatty acids with risk of total mortality (n = 1456)

From: Plasma trans-fatty acids levels and mortality: a cohort study based on 1999–2000 National Health and Nutrition Examination Survey (NHANES)

  Events (n/%) Number at risk (Person-years) Model 1 Model 2 Model 3
Hazard ratio
(95% CI)
P value Hazard ratio
(95% CI)
P value Hazard ratio
(95% CI)
P value
Elaidic acid (C18:1 t9), μM
Per 10 units increase 221 (15.2) 1456 (16034) 1.07(1.02–1.13) 0.010 1.13(1.05–1.22) 0.002 1.30(1.08–1.56) 0.005
Per sd increase 1.17(1.04–1.31) 0.010 1.31(1.11–1.56) 0.002 1.79(1.19–2.67) 0.005
Quartile (Range, μM)
 Quartile 1 (4.5–23.4) 51(14.0) 363(3974) 1.20(0.80–1.78) 0.377 1.35(0.89–2.04) 0.162 1.37(0.89–2.09) 0.154
 Quartile 2 (23.5–32.3) 47(12.9) 363(4078) Reference   Reference   Reference  
 Quartile 3 (32.4–44.7) 55(15.0) 366(4048) 1.39(0.93–2.05) 0.104 1.49(1.00–2.22) 0.051 1.48(0.99–2.24) 0.059
 Quartile 4 (44.9–238) 68(18.7) 364(3934) 1.63(1.12–2.38) 0.010 2.01(1.30–3.08) 0.002 2.00(1.18–3.40) 0.010
Vaccenic acid (C18:1 t11), μM
Per 10 units increase 221 (15.2) 1456 (16034) 1.05(0.99–1.09) 0.053 1.08(1.01–1.15) 0.020 0.92(0.80–1.06) 0.241
Per sd increase 1.12(0.99–1.25) 0.053 1.20(1.03–1.40) 0.020 0.81(0.57–1.15) 0.241
Quartile (Range, μM)
 Quartile 1 (4.45–27.9) 54(14.8) 364(3997) 0.93(0.64–1.35) 0.707 0.95(0.64–1.41) 0.811 1.00(0.67–1.49) 0.999
 Quartile 2 (27.9–37.5) 55(15.2) 363(4019) Reference   Reference   Reference  
 Quartile 3 (37.6–49.7) 49(13.5) 364(4036) 0.89(0.60–1.31) 0.549 1.04(0.70–1.54) 0.865 0.93(0.62–1.41) 0.743
 Quartile 4 (49.8–313) 63(17.3) 365(3982) 1.23(0.85–1.76) 0.271 1.39(0.92–2.12) 0.119 0.99(0.57–1.71) 0.969
Palmitelaidic acid (C16:1 t9), μM
Per unit increase 221 (15.2) 1456 (16034) 1.02(0.99–1.06) 0.247 1.04(0.99–1.09) 0.106 1.00(0.94–1.07) 0.896
Per sd increase 1.08(0.95–1.23) 0.247 1.16(0.97–1.39) 0.106 1.02(0.80–1.29) 0.896
Quartile (Range, μM)
 Quartile 1 (1.1–5.1) 45(12.4) 363(3989) 1.06(0.71–1.59) 0.758 1.11(0.73–1.69) 0.628 1.15(0.76–1.76) 0.510
 Quartile 2 (5.1–6.8) 54(14.8) 365(4060) Reference   Reference   Reference  
 Quartile 3 (6.9–9.4) 55(15.1) 364(4057) 0.95(0.65–1.38) 0.776 1.10(0.74–1.62) 0.639 1.05(0.70–1.57) 0.817
 Quartile 4 (9.4–33.1) 67(18.4) 364(3928) 1.35(0.95–1.94) 0.098 1.82(1.19–2.80) 0.006 1.49(0.91–2.43) 0.115
Linolelaidic acid (C18:2 t9, 12), μM
Per unit increase 221 (15.2) 1456 (16034) 1.04(0.96–1.13) 0.370 1.05(0.92–1.19) 0.487 0.86(0.73–1.02) 0.088
Per sd 1.06(0.93–1.21) 0.370 1.08(0.88–1.32) 0.487 0.79(0.60–1.04) 0.088
Quartile (Range, μM)
 Quartile 1 (0.7–2.0) 55(15.1) 364(3975) 1.16(0.80–1.69) 0.423 1.30(0.88–1.92) 0.187 1.46(0.98–2.19) 0.063
 Quartile 2 (2.0–2.7) 56(15.4) 363(4004) Reference   Reference   Reference  
 Quartile 3 (2.7–3.7) 54(14.8) 365(4057) 1.41(0.97–2.06) 0.075 1.49(1.01–2.20) 0.047 1.30(0.87–1.94) 0.200
 Quartile 4 (3.7–13.4) 56(15.4) 364(3998) 1.27(0.87–1.85) 0.214 1.26(0.81–1.96) 0.302 0.86(0.52–1.42) 0.561
  1. Model 1: adjusted for age, gender at baseline
  2. Model 2: further adjusted for race, body mass index, systolic blood pressure, diastolic blood pressure, fasting plasma glucose, triglyceride, total cholesterol, high density lipoprotein, uric acid, estimation glomerular filtration rate, alcohol use, smoking, and self-reported cardiovascular diseases history at baseline
  3. Model 3: further adjusted for other trans-fatty acid subtypes